Rare Case of Neuroendocrine Tumor of Common Bile Duct Identified With Somatostatin Receptor But Not With Glucose Transporter Imaging. (16th November 2022)

• Record Type: Journal Article
• Authors: Mohite, Ashish; Shukla, Varun; M V, Manikandan; Chowdhury, Zachariah; Chaturvedi, Meenakshi
• Is Part Of: Clinical nuclear medicine. Volume 47:Number 11(2022)
• Page Start: e715
• Page End: e717
• Publication Date: 2022-11-16
• Subjects: common bile duct -- glucose transporter imaging -- neuroendocrine tumor -- SSTR imaging; Nuclear medicine -- Periodicals; Radioisotope scanning -- Periodicals; Nuclear Medicine -- Periodicals; 616.07575
• DOI: 10.1097/RLU.0000000000004342
• Languages: English
• ISSNs: 0363-9762

Abstract

Abstract: Neuroendocrine tumors (NETs) are heterogeneous group of tumors arising from enterochromaffin cells. Neuroendocrine tumors are most commonly found in bowel and pancreatic tissue. Because of paucity of enterochromaffin cells in biliary tract, NETs of bile duct are very rare. Most of the neoplasms in the extrahepatic bile duct are adenocarcinomas; only 0.2% to 0.3% of NETs arise from the bile duct. Cases reported in the literature of biliary carcinoid are diagnosed postoperatively on histopathologic evaluation. We hereby demonstrate a rare presentation of CBD NET identified preoperatively on somatostatin receptor but not on glucose transporter imaging, confirmed by histopathology and immunohistochemistry to be grade 2 NET (Ki-67, 20%).